• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Ocugen (OCGN)

Common Shares
Sell: $1.38|Buy: $1.39|Change: 0.04 (2.99%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Address

5 Great Valley Parkway
Suite 160
Malvern
PA
USA
19355

Telephone

+1 484 3284698

Website

https://www.ocugen.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Ocugen Inc First Quarter Earnings Conference Call for 20272027-05-05T08:30:00
Ocugen Inc First Quarter Earnings Results for 20272027-05-05T00:00:00
Ocugen Inc Fourth Quarter Earnings Conference Call for 20262027-03-04T08:30:00
Ocugen Inc Fourth Quarter Earnings Results for 20262027-03-04T00:00:00
Ocugen Inc Annual Report for 20262027-03-04T00:00:00
Ocugen Inc Third Quarter Earnings Conference Call for 20262026-11-05T08:30:00
Ocugen Inc Third Quarter Earnings Results for 20262026-11-05T00:00:00
Ocugen Inc Second Quarter Earnings Conference Call for 20262026-07-31T08:30:00
Ocugen Inc Second Quarter Earnings Results for 20262026-07-31T00:00:00
Ocugen Inc Annual General Meeting for 20262026-06-11T08:00:00
Stifel 2026 Virtual Ophthalmology Forum2026-05-26T10:30:00
Ocugen Inc First Quarter Earnings Conference Call for 20262026-05-05T08:30:00
Ocugen Inc First Quarter Earnings Result for 20262026-05-05T00:00:00

Previous key dates

NameKey Date
Stifel 2026 Virtual Ophthalmology Forum2026-05-26T10:30:00
Ocugen Inc First Quarter Earnings Conference Call for 20262026-05-05T08:30:00
Ocugen Inc First Quarter Earnings Result for 20262026-05-05T00:00:00
Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit2026-04-28T08:20:00
Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration2026-03-24T08:00:00
Ocugen Inc Fourth Quarter Earnings Conference Call for 20252026-03-04T08:30:00
Ocugen Inc Fourth Quarter Earnings Results for 20252026-03-04T00:00:00
Ocugen Inc Annual Report for 20252026-03-04T00:00:00
44(th) Annual J.P. Morgan Healthcare Conference2026-01-15T09:45:00
44th Annual J.P. Morgan Healthcare Conference2026-01-15T09:45:00
Ocugen, Inc. Call2026-01-15T08:30:00
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration2026-01-15T08:30:00
NobleCon21—Noble Capital Markets’Twenty-FirstAnnual EmergingGrowth Equity Conference2025-12-03T13:00:00
Ocugen Inc Third Quarter Earnings Conference Call for 20252025-11-05T08:30:00
Ocugen Inc Third Quarter Earnings Result for 20252025-11-05T00:00:00
Biotech on Tap2025-09-25T15:30:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T17:00:00
Ocugen Inc Second Quarter Earnings Conference Call for 20252025-08-01T08:30:00
Ocugen Inc Second Quarter Earnings Result for 20252025-08-01T00:00:00
Ocugen Inc Annual General Meeting for 20252025-06-05T08:00:00
Ocugen Inc First Quarter Earnings Conference Call for 20252025-05-09T08:30:00
Ocugen Inc First Quarter Earnings Results for 20252025-05-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.